<?xml version="1.0"?>
<presentation title="10 Tae Jun Song" width="720.0000000" height="540.0000000" thmbWidth="78.0000000" thmbHeight="59.0000000" frameRate="24.0000000" looping="0" startingSlideShow="" pptVersion="2010" type="compound" hasExternalAudio="0" uid="{985E8370-6D72-40E3-90C9-59A37C99208E}">
	<presenters>
		<presenter name="Tae Jun Song" title="Korea" email="" web="" phone="" photoAssetId="">
			<bio>Impact of EUS-FNA/B in pancreatic mass</bio>
		</presenter>
	</presenters>
	<references/>
	<soundAssets>
		<soundAsset id="sndAsset0" src="sound1.mp3" embedded="0" size="487908" duration="17425"/>
		<soundAsset id="sndAsset1" src="sound2.mp3" embedded="0" size="849234" duration="30329"/>
		<soundAsset id="sndAsset2" src="sound3.mp3" embedded="0" size="969188" duration="34613"/>
		<soundAsset id="sndAsset3" src="sound4.mp3" embedded="0" size="707336" duration="25262"/>
		<soundAsset id="sndAsset4" src="sound5.mp3" embedded="0" size="733668" duration="26202"/>
		<soundAsset id="sndAsset5" src="sound6.mp3" embedded="0" size="494491" duration="17660"/>
		<soundAsset id="sndAsset6" src="sound7.mp3" embedded="0" size="1213485" duration="43338"/>
		<soundAsset id="sndAsset7" src="sound8.mp3" embedded="0" size="902628" duration="32236"/>
		<soundAsset id="sndAsset8" src="sound9.mp3" embedded="0" size="323336" duration="11547"/>
		<soundAsset id="sndAsset9" src="sound10.mp3" embedded="0" size="994056" duration="35502"/>
		<soundAsset id="sndAsset10" src="sound11.mp3" embedded="0" size="710262" duration="25366"/>
		<soundAsset id="sndAsset11" src="sound12.mp3" embedded="0" size="613714" duration="21918"/>
		<soundAsset id="sndAsset12" src="sound13.mp3" embedded="0" size="505462" duration="18052"/>
		<soundAsset id="sndAsset13" src="sound14.mp3" embedded="0" size="781942" duration="27926"/>
		<soundAsset id="sndAsset14" src="sound15.mp3" embedded="0" size="762925" duration="27247"/>
		<soundAsset id="sndAsset15" src="sound16.mp3" embedded="0" size="397942" duration="14212"/>
		<soundAsset id="sndAsset16" src="sound17.mp3" embedded="0" size="446948" duration="15962"/>
		<soundAsset id="sndAsset17" src="sound18.mp3" embedded="0" size="590308" duration="21082"/>
		<soundAsset id="sndAsset18" src="sound19.mp3" embedded="0" size="370148" duration="13219"/>
		<soundAsset id="sndAsset19" src="sound20.mp3" embedded="0" size="645165" duration="23041"/>
		<soundAsset id="sndAsset20" src="sound21.mp3" embedded="0" size="554468" duration="19802"/>
		<soundAsset id="sndAsset21" src="sound22.mp3" embedded="0" size="288228" duration="10293"/>
		<soundAsset id="sndAsset22" src="sound23.mp3" embedded="0" size="835336" duration="29833"/>
		<soundAsset id="sndAsset23" src="sound24.mp3" embedded="0" size="474742" duration="16955"/>
		<soundAsset id="sndAsset24" src="sound25.mp3" embedded="0" size="1016731" duration="36311"/>
		<soundAsset id="sndAsset25" src="sound26.mp3" embedded="0" size="1207634" duration="43129"/>
		<soundAsset id="sndAsset26" src="sound27.mp3" embedded="0" size="1445348" duration="51619"/>
		<soundAsset id="sndAsset27" src="sound28.mp3" embedded="0" size="1074514" duration="38375"/>
		<soundAsset id="sndAsset28" src="sound29.mp3" embedded="0" size="1020388" duration="36442"/>
		<soundAsset id="sndAsset29" src="sound30.mp3" embedded="0" size="982354" duration="35084"/>
		<soundAsset id="sndAsset30" src="sound31.mp3" embedded="0" size="878491" duration="31374"/>
		<soundAsset id="sndAsset31" src="sound32.mp3" embedded="0" size="70994" duration="2535"/>
	</soundAssets>
	<sharedAssetsLibrary src="assets.swf"/>
	<graphicAssets>
		<graphicAsset id="imgAsset0" src="thmb1.swf" embedded="0"/>
		<graphicAsset id="imgAsset1" src="thmb2.swf" embedded="0"/>
		<graphicAsset id="imgAsset2" src="thmb3.swf" embedded="0"/>
		<graphicAsset id="imgAsset3" src="thmb4.swf" embedded="0"/>
		<graphicAsset id="imgAsset4" src="thmb5.swf" embedded="0"/>
		<graphicAsset id="imgAsset5" src="thmb6.swf" embedded="0"/>
		<graphicAsset id="imgAsset6" src="thmb7.swf" embedded="0"/>
		<graphicAsset id="imgAsset7" src="thmb8.swf" embedded="0"/>
		<graphicAsset id="imgAsset8" src="thmb9.swf" embedded="0"/>
		<graphicAsset id="imgAsset9" src="thmb10.swf" embedded="0"/>
		<graphicAsset id="imgAsset10" src="thmb11.swf" embedded="0"/>
		<graphicAsset id="imgAsset11" src="thmb12.swf" embedded="0"/>
		<graphicAsset id="imgAsset12" src="thmb13.swf" embedded="0"/>
		<graphicAsset id="imgAsset13" src="thmb14.swf" embedded="0"/>
		<graphicAsset id="imgAsset14" src="thmb15.swf" embedded="0"/>
		<graphicAsset id="imgAsset15" src="thmb16.swf" embedded="0"/>
		<graphicAsset id="imgAsset16" src="thmb17.swf" embedded="0"/>
		<graphicAsset id="imgAsset17" src="thmb18.swf" embedded="0"/>
		<graphicAsset id="imgAsset18" src="thmb19.swf" embedded="0"/>
		<graphicAsset id="imgAsset19" src="thmb20.swf" embedded="0"/>
		<graphicAsset id="imgAsset20" src="thmb21.swf" embedded="0"/>
		<graphicAsset id="imgAsset21" src="thmb22.swf" embedded="0"/>
		<graphicAsset id="imgAsset22" src="thmb23.swf" embedded="0"/>
		<graphicAsset id="imgAsset23" src="thmb24.swf" embedded="0"/>
		<graphicAsset id="imgAsset24" src="thmb25.swf" embedded="0"/>
		<graphicAsset id="imgAsset25" src="thmb26.swf" embedded="0"/>
		<graphicAsset id="imgAsset26" src="thmb27.swf" embedded="0"/>
		<graphicAsset id="imgAsset27" src="thmb28.swf" embedded="0"/>
		<graphicAsset id="imgAsset28" src="thmb29.swf" embedded="0"/>
		<graphicAsset id="imgAsset29" src="thmb30.swf" embedded="0"/>
		<graphicAsset id="imgAsset30" src="thmb31.swf" embedded="0"/>
		<graphicAsset id="imgAsset31" src="thmb32.swf" embedded="0"/>
	</graphicAssets>
	<backgroundSound soundAssetId="" looping="0" volume="1.0000000"/>
	<narration>
		<audioTracks>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset0">
				<startTimestamp slideIndex="0" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="0" stepIndex="0" timeOffset="17.3840000"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset1">
				<startTimestamp slideIndex="1" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="1" stepIndex="0" timeOffset="30.2970000"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset2">
				<startTimestamp slideIndex="2" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="2" stepIndex="0" timeOffset="34.5680000"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset3">
				<startTimestamp slideIndex="3" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="3" stepIndex="0" timeOffset="25.2250000"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset4">
				<startTimestamp slideIndex="4" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="4" stepIndex="0" timeOffset="26.1590000"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset5">
				<startTimestamp slideIndex="5" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="5" stepIndex="0" timeOffset="17.6180000"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset6">
				<startTimestamp slideIndex="6" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="6" stepIndex="0" timeOffset="43.3100000"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset7">
				<startTimestamp slideIndex="7" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="7" stepIndex="0" timeOffset="32.1990000"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset8">
				<startTimestamp slideIndex="8" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="8" stepIndex="0" timeOffset="11.5109997"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset9">
				<startTimestamp slideIndex="9" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="9" stepIndex="0" timeOffset="35.4690000"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset10">
				<startTimestamp slideIndex="10" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="10" stepIndex="0" timeOffset="25.3250000"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset11">
				<startTimestamp slideIndex="11" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="11" stepIndex="0" timeOffset="21.8890000"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset12">
				<startTimestamp slideIndex="12" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="12" stepIndex="0" timeOffset="18.0180000"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset13">
				<startTimestamp slideIndex="13" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="13" stepIndex="0" timeOffset="27.8950000"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset14">
				<startTimestamp slideIndex="14" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="14" stepIndex="0" timeOffset="27.1940000"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset15">
				<startTimestamp slideIndex="15" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="15" stepIndex="0" timeOffset="14.1809998"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset16">
				<startTimestamp slideIndex="16" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="16" stepIndex="0" timeOffset="15.9160000"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset17">
				<startTimestamp slideIndex="17" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="17" stepIndex="0" timeOffset="21.0540000"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset18">
				<startTimestamp slideIndex="18" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="18" stepIndex="0" timeOffset="13.1800000"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset19">
				<startTimestamp slideIndex="19" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="19" stepIndex="0" timeOffset="22.9899998"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset20">
				<startTimestamp slideIndex="20" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="20" stepIndex="0" timeOffset="19.7530000"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset21">
				<startTimestamp slideIndex="21" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="21" stepIndex="0" timeOffset="10.2440000"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset22">
				<startTimestamp slideIndex="22" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="22" stepIndex="0" timeOffset="29.7960000"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset23">
				<startTimestamp slideIndex="23" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="23" stepIndex="0" timeOffset="16.9170000"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset24">
				<startTimestamp slideIndex="24" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="24" stepIndex="0" timeOffset="36.2700000"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset25">
				<startTimestamp slideIndex="25" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="25" stepIndex="0" timeOffset="43.0760000"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset26">
				<startTimestamp slideIndex="26" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="26" stepIndex="0" timeOffset="51.5849991"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset27">
				<startTimestamp slideIndex="27" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="27" stepIndex="0" timeOffset="38.3380000"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset28">
				<startTimestamp slideIndex="28" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="28" stepIndex="0" timeOffset="36.4029999"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset29">
				<startTimestamp slideIndex="29" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="29" stepIndex="0" timeOffset="35.0349998"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset30">
				<startTimestamp slideIndex="30" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="30" stepIndex="0" timeOffset="31.3309994"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset31">
				<startTimestamp slideIndex="31" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="31" stepIndex="0" timeOffset="2.5020000"/>
			</audioTrack>
		</audioTracks>
	</narration>
	<settings>
		<navigation>
			<keyboard enabled="1">
				<actions>
					<action name="playPause">
						<shortcut code="32" control="0" shift="0"/>
					</action>
					<action name="nextSlide">
						<shortcut code="34" control="0" shift="0"/>
					</action>
					<action name="previousSlide">
						<shortcut code="33" control="0" shift="0"/>
					</action>
					<action name="nextStep">
						<shortcut code="13" control="0" shift="0"/>
					</action>
					<action name="previousStep">
						<shortcut code="13" control="0" shift="1"/>
					</action>
					<action name="firstSlide">
						<shortcut code="36" control="1" shift="0"/>
					</action>
					<action name="lastSlide">
						<shortcut code="35" control="1" shift="0"/>
					</action>
					<action name="lastViewedSlide">
						<shortcut code="8" control="0" shift="0"/>
					</action>
					<action name="slideStart">
						<shortcut code="36" control="0" shift="0"/>
					</action>
					<action name="slideEnd">
						<shortcut code="35" control="0" shift="0"/>
					</action>
					<action name="seekForward">
						<shortcut code="39" control="0" shift="0"/>
					</action>
					<action name="seekBackward">
						<shortcut code="37" control="0" shift="0"/>
					</action>
					<action name="volumeUp">
						<shortcut code="38" control="0" shift="0"/>
					</action>
					<action name="volumeDown">
						<shortcut code="40" control="0" shift="0"/>
					</action>
					<action name="toggleFullscreen">
						<shortcut code="70" control="1" shift="0"/>
					</action>
				</actions>
			</keyboard>
			<mouse enabled="1" target="step"/>
			<gesture zoom="1"/>
		</navigation>
		<skin>
			<colorSettings>
				<color id="button.content.normal">#FFFFFF</color>
				<color id="button.content.over">#FFFFFF</color>
				<color id="button.face.normal">#777777</color>
				<color id="button.face.over">#575757</color>
				<color id="companyLogo.background">#FFFFFF</color>
				<color id="hyperlink">#097CE7</color>
				<color id="listItem.face.over">#E8E8E8</color>
				<color id="listItem.face.pressed">#6E6E6E</color>
				<color id="listItem.label.over">#000000</color>
				<color id="listItem.label.pressed">#FFFFFF</color>
				<color id="listItem.label.visited">#A1A1A1</color>
				<color id="page.background">#8A8A8A</color>
				<color id="panel.background">#F7F7F7</color>
				<color id="panel.text">#323232</color>
				<color id="player.background">#D4D4D4</color>
				<color id="popup.background">#FFFFFF</color>
				<color id="progress.background">#6E6E6E</color>
				<color id="progress.loading">#D0D0D0</color>
				<color id="progress.playback">#A1A1A1</color>
				<color id="text">#4D4D4D</color>
			</colorSettings>
			<controlPanelSettings>
				<visible>true</visible>
				<showOutline>false</showOutline>
				<showPlayPause>true</showPlayPause>
				<showRewind>true</showRewind>
				<showVolumeControl>true</showVolumeControl>
				<showCCButton>false</showCCButton>
				<showPrevButton>true</showPrevButton>
				<showNextButton>true</showNextButton>
				<showSlideOnlyButton>true</showSlideOnlyButton>
				<progressBar>
					<visible>true</visible>
					<enabled>true</enabled>
					<showLabels>true</showLabels>
					<mode>slideTimeline</mode>
				</progressBar>
				<navigationMode>bySlides</navigationMode>
			</controlPanelSettings>
			<titlePanelSettings>
				<showLogo>false</showLogo>
				<visible>true</visible>
				<buttons>
					<button type="attachments" visible="false"/>
					<button type="presenterInfo" visible="false"/>
					<button type="markerTools" visible="true"/>
					<button type="notes" visible="false"/>
					<button type="outline" visible="false"/>
				</buttons>
			</titlePanelSettings>
			<outlinePanelSettings>
				<numberEntries>true</numberEntries>
				<highlightViewedEntries>true</highlightViewedEntries>
				<thumbnails>true</thumbnails>
				<search>true</search>
				<multilevel>true</multilevel>
			</outlinePanelSettings>
			<sidePanelSettings>
				<showAtLeft>true</showAtLeft>
				<showLogo>false</showLogo>
				<showPresenterInfo>true</showPresenterInfo>
				<showPresenterVideo>false</showPresenterVideo>
				<visible>true</visible>
				<tabsPanel>
					<showOutline>true</showOutline>
					<showNotes>false</showNotes>
				</tabsPanel>
			</sidePanelSettings>
		</skin>
		<appearance fullScreen="1" showSlidePreloader="1"/>
		<playback autoStart="1" syncWithVideoNarration="1" enableVideoControl="1" resumePresentationPlayback="always"/>
	</settings>
	<slides embedded="0">
		<slide index="0" title="Impact of EUS-FNA/B in Pancreatic mass" titleNormalized="impact of eus-fna/b in pancreatic mass" src="slide1.swf" size="1075882" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset0" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="17.3830008"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
			<text>Taejun Song

Division of Gastroenterology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea

Impact of EUS-FNA/B in Pancreatic mass</text>
		</slide>
		<slide index="1" title="EUS-FNA/B of pancreatic mass" titleNormalized="eus-fna/b of pancreatic mass" src="slide2.swf" size="79389" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset1" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="30.2989992"/>
			</animationSteps>
			<notes>•	EUS-FNA/B is a commonly used method for deﬁnitive tissue diagnosis of suspicious pancreatic lesions, with an overall sensitivity of 85%, speciﬁcity of 98%, respectively.
•	This procedure is generally very safe with a procedure-related morbidity of less than 1% and very low mortality.</notes>
			<notesNormalized>•	eus-fna/b is a commonly used method for deﬁnitive tissue diagnosis of suspicious pancreatic lesions, with an overall sensitivity of 85%, speciﬁcity of 98%, respectively.
•	this procedure is generally very safe with a procedure-related morbidity of less than 1% and very low mortality.</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;•	EUS-FNA/B is a commonly used method for deﬁnitive tissue diagnosis of suspicious pancreatic lesions, with an overall sensitivity of 85%, speciﬁcity of 98%, respectively.&lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;•	This procedure is generally very safe with a procedure-related morbidity of less than 1% and very low mortality.&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>EUS-FNA/B of pancreatic mass
Endoscopic ultrasound-guided ﬁne needle aspiration/biopsy (EUS-FNA/B) is a commonly used method for deﬁnitive tissue diagnosis of suspicious pancreatic lesions. 

Sensitivity: 85%
Speciﬁcity: 98%
Morbidity: 0.98%
Mortality: 0.02%
Ngamruengphong et al. Gut 2015;64:1105–1110</text>
		</slide>
		<slide index="2" title="Misdiagnosis of pancreatic mass" titleNormalized="misdiagnosis of pancreatic mass" src="slide3.swf" size="148833" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset2" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="34.5689997"/>
			</animationSteps>
			<notes>•	Misdiagnosis of pancreas mass frequently occurs in two clinical settings. 
•	First, patients with benign lesion may be inappropriately treated with operative resection in suspicion of pancreatic cancer.
•	Second, patients with pancreatic cancer may be treated with corticosteroids or conservative treatment for extended periods in suspicion of benign pancreatic lesion such as autoimmune pancreatitis.</notes>
			<notesNormalized>•	misdiagnosis of pancreas mass frequently occurs in two clinical settings. 
•	first, patients with benign lesion may be inappropriately treated with operative resection in suspicion of pancreatic cancer.
•	second, patients with pancreatic cancer may be treated with corticosteroids or conservative treatment for extended periods in suspicion of benign pancreatic lesion such as autoimmune pancreatitis.</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;•	Misdiagnosis of pancreas mass frequently occurs in two clinical settings. &lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;•	First, patients with benign lesion may be inappropriately treated with operative resection in suspicion of pancreatic cancer.&lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;•	Second, patients with pancreatic cancer may be treated with corticosteroids or conservative treatment for extended periods in suspicion of benign pancreatic lesion such as autoimmune pancreatitis.&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Misdiagnosis of pancreatic mass
Misdiagnosis of pancreas mass occurs in two clinical settings.
Patients with benign lesion being inappropriately treated with operative resection
Patients with pancreatic cancer (PCa) treated with corticosteroids or conservative treatment for extended periods
Pancreatic cancer 
AIP</text>
		</slide>
		<slide index="3" title="Distal pancreas mass" titleNormalized="distal pancreas mass" src="slide4.swf" size="118687" advanceOnTime="1" framesCount="236" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset3" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="235" playTime="9.7916667" pauseTime="15.4383329"/>
			</animationSteps>
			<notes>•	Here are several cases of pancreas body or tail mass. 
•	Which one is pancreatic cancer? 
•	Pancreatic cancer is number 3.
•	In many cases, CT scan shows atypical or indeterminate image findings. And in these cases, eventually histologic confirmation is needed.
</notes>
			<notesNormalized>•	here are several cases of pancreas body or tail mass. 
•	which one is pancreatic cancer? 
•	pancreatic cancer is number 3.
•	in many cases, ct scan shows atypical or indeterminate image findings. and in these cases, eventually histologic confirmation is needed.
</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;•	Here are several cases of pancreas body or tail mass. &lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;•	Which one is pancreatic cancer? &lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;•	Pancreatic cancer is number 3.&lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;•	In many cases, CT scan shows atypical or indeterminate image findings. And in these cases, eventually histologic confirmation is needed.&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Distal pancreas mass
Autoimmune pancreatitis
Autoimmune pancreatitis
Pancreatic cancer
Solid pseudopapillary neoplasm
1
2
3
4</text>
		</slide>
		<slide index="4" title="EUS-FNA of pancreatic mass" titleNormalized="eus-fna of pancreatic mass" src="slide5.swf" size="2543" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset4" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="26.1589998"/>
			</animationSteps>
			<notes>•	EUS-FNA/B have been used before pancreatic surgery more and more often.
•	The main objectives of preoperative EUS-FNA/B are
•	To accurately identify malignant lesions 
•	To spare the patients with benign condition 
•	To avoid unnecessary surgical resections </notes>
			<notesNormalized>•	eus-fna/b have been used before pancreatic surgery more and more often.
•	the main objectives of preoperative eus-fna/b are
•	to accurately identify malignant lesions 
•	to spare the patients with benign condition 
•	to avoid unnecessary surgical resections</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;•	EUS-FNA/B have been used before pancreatic surgery more and more often.&lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;•	The main objectives of preoperative EUS-FNA/B are&lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;•	To accurately identify malignant lesions &lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;•	To spare the patients with benign condition &lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;•	To avoid unnecessary surgical resections &lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>EUS-FNA of pancreatic mass
EUS-FNA/B have been used before pancreatic surgery more and more often.
The main objectives of preoperative EUS-FNA/B 
To accurately identify malignant lesions 
To spare the patients with benign condition 
To avoid unnecessary surgical resections</text>
		</slide>
		<slide index="5" title="Trends in the use of EUS-FNA in patients with resectable PCa" titleNormalized="trends in the use of eus-fna in patients with resectable pca" src="slide6.swf" size="49476" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset5" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="17.6190008"/>
			</animationSteps>
			<notes>•	In the United States, overall use of preoperative EUS-FNA increased during the past decade, with 10% in 2001 to 47% in 2009. </notes>
			<notesNormalized>•	in the united states, overall use of preoperative eus-fna increased during the past decade, with 10% in 2001 to 47% in 2009.</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;•	In the United States, overall use of preoperative EUS-FNA increased during the past decade, with 10% in 2001 to 47% in 2009. &lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Trends in the use of EUS-FNA in patients
with resectable PCa
2001 : 10%
2009 : 47.1%

Ngamruengphong et al. Gut 2015;64:1105–1110</text>
		</slide>
		<slide index="6" title="Preoperative EUS-FNA/B of PCa: Pros" titleNormalized="preoperative eus-fna/b of pca: pros" src="slide7.swf" size="2596" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset6" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="43.3090014"/>
			</animationSteps>
			<notes>Why do we perform the preoperative EUS-FNA?
Here are the arguments favoring a preoperative pancreatic biopsy.
It has very good accuracy.</notes>
			<notesNormalized>why do we perform the preoperative eus-fna?
here are the arguments favoring a preoperative pancreatic biopsy.
it has very good accuracy.</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;Why do we perform the preoperative EUS-FNA?&lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;Here are the arguments favoring a preoperative pancreatic biopsy.&lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;It has very good accuracy.&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Preoperative EUS-FNA/B of PCa: Pros
Arguments favoring a preoperative pancreatic biopsy
Has very good accuracy
Is a safe procedure
Increases surgeon’s conﬁdence
Increases patient’s convincement
Avoids unnecessary surgery (in “mimickers”)
Allows neoadjuvant chemotherapy

Dig Liver Dis 2019;51:4-9</text>
		</slide>
		<slide index="7" title="Preoperative EUS-FNA of PCa: Cons" titleNormalized="preoperative eus-fna of pca: cons" src="slide8.swf" size="2488" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset7" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="32.1990008"/>
			</animationSteps>
			<notes>•	On the other hands, here are arguments against a preoperative biopsy.
•	Available imaging techniques already have high diagnostic sensitivity


</notes>
			<notesNormalized>•	on the other hands, here are arguments against a preoperative biopsy.
•	available imaging techniques already have high diagnostic sensitivity


</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;•	On the other hands, here are arguments against a preoperative biopsy.&lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;•	Available imaging techniques already have high diagnostic sensitivity&lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;</notesHtml>
			<text>Preoperative EUS-FNA of PCa: Cons
Arguments against a preoperative biopsy 
Available imaging techniques have high diagnostic sensitivity
A negative result may not exclude malignancy 
Potential seeding can hamper curative surgery
Can delay patient’s treatment
Dig Liver Dis 2019;51:4-9</text>
		</slide>
		<slide index="8" title="Tumor seeding after EUS-FNA" titleNormalized="tumor seeding after eus-fna" src="slide9.swf" size="168276" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset8" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="11.5099997"/>
			</animationSteps>
			<notes>•	There have been several case reports of tumor seeding after EUS-FNA/B. 
</notes>
			<notesNormalized>•	there have been several case reports of tumor seeding after eus-fna/b. 
</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;•	There have been several case reports of tumor seeding after EUS-FNA/B. &lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Tumor seeding after EUS-FNA
Paquin et al. Gastrointest Endosc 2005;61:610-1
Chong et al. Gastrointest Endosc 2011;74:933-5
Ahmed et al. Gastrointest Endosc 2011;74:231-3</text>
		</slide>
		<slide index="9" title="Tumor seeding after EUS-FNA" titleNormalized="tumor seeding after eus-fna" src="slide10.swf" size="2780" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset9" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="35.4690012"/>
			</animationSteps>
			<notes>•	From 2003 to 2016, 14 cases of needle tract seeding following EUS-guided sampling have been reported.
•	Several cases of tumor seeding along a needle tract in pancreatic adenocarcinoma occurring at the gastric wall following EUS-FNA of pancreatic body or tail have been reported.
•	However, this has never been reported for EUS-FNA of pancreatic head lesions.
</notes>
			<notesNormalized>•	from 2003 to 2016, 14 cases of needle tract seeding following eus-guided sampling have been reported.
•	several cases of tumor seeding along a needle tract in pancreatic adenocarcinoma occurring at the gastric wall following eus-fna of pancreatic body or tail have been reported.
•	however, this has never been reported for eus-fna of pancreatic head lesions.
</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;•	From 2003 to 2016, 14 cases of needle tract seeding following EUS-guided sampling have been reported.&lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;•	Several cases of tumor seeding along a needle tract in pancreatic adenocarcinoma occurring at the gastric wall following EUS-FNA of pancreatic body or tail have been reported.&lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;•	However, this has never been reported for EUS-FNA of pancreatic head lesions.&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Tumor seeding after EUS-FNA
From 2003 to 2016, only 14 cases of needle tract seeding following EUS-guided sampling have been reported.

Several cases of tumor seeding along a needle tract in pancreatic cancer occurring at the gastric wall following EUS-FNA of pancreatic body/tail have been reported.

Tumor seeding along a needle tract has never been reported for EUS-FNA of pancreatic head lesions.
Ngamruengphong et al. Gut 2015;64:1105–1110
Dumonceau et al. Endoscopy 2017;49:695-714</text>
		</slide>
		<slide index="10" title="EUS-FNA/B for pancreas head lesion" titleNormalized="eus-fna/b for pancreas head lesion" src="slide11.swf" size="408066" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset10" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="25.3289999"/>
			</animationSteps>
			<notes>•	As you can see, pancreaticoduodenectomy removes the duodenum, so it can also remove the needle tract, potential sites of seeding. 
•	As a result, the risk of tumor seeding is very low.</notes>
			<notesNormalized>•	as you can see, pancreaticoduodenectomy removes the duodenum, so it can also remove the needle tract, potential sites of seeding. 
•	as a result, the risk of tumor seeding is very low.</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;•	As you can see, pancreaticoduodenectomy removes the duodenum, so it can also remove the needle tract, potential sites of seeding. &lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;•	As a result, the risk of tumor seeding is very low.&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>EUS-FNA/B for pancreas head lesion</text>
		</slide>
		<slide index="11" title="EUS-FNA/B for distal pancreas lesion" titleNormalized="eus-fna/b for distal pancreas lesion" src="slide12.swf" size="368468" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset11" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="21.8889994"/>
			</animationSteps>
			<notes>•	On the other hand, in case of the pancreas body or tail mass, EUS-FNA was done through the stomach.
•	But distal pancreatectomy does not remove stomach puncture site and needle tract. 
•	So there is a risk of stomach recurrence and tract seeding.</notes>
			<notesNormalized>•	on the other hand, in case of the pancreas body or tail mass, eus-fna was done through the stomach.
•	but distal pancreatectomy does not remove stomach puncture site and needle tract. 
•	so there is a risk of stomach recurrence and tract seeding.</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;•	On the other hand, in case of the pancreas body or tail mass, EUS-FNA was done through the stomach.&lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;•	But distal pancreatectomy does not remove stomach puncture site and needle tract. &lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;•	So there is a risk of stomach recurrence and tract seeding.&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>EUS-FNA/B for distal pancreas lesion</text>
		</slide>
		<slide index="12" title="AMC experiences" titleNormalized="amc experiences" src="slide13.swf" size="152067" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset12" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="18.0190005"/>
			</animationSteps>
			<notes>•	We retrospectively review the data of our center to evaluate the safety and benefit of preoperative EUS-FNA/B for the resectable distal PCa.</notes>
			<notesNormalized>•	we retrospectively review the data of our center to evaluate the safety and benefit of preoperative eus-fna/b for the resectable distal pca.</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;•	We retrospectively review the data of our center to evaluate the safety and benefit of preoperative EUS-FNA/B for the resectable distal PCa.&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>AMC experiences
We retrospectively review the data of our center to evaluate the safety and benefit of preoperative EUS-FNA/B for the resectable distal PCa.</text>
		</slide>
		<slide index="13" title="Trends in the use of EUS-FNA/B in patients with resectable distal pancreatic cancer" titleNormalized="trends in the use of eus-fna/b in patients with resectable distal pancreatic cancer" src="slide14.swf" size="10329" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset13" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="27.8989996"/>
			</animationSteps>
			<notes>•	In our center, EUS-FNA have been increasingly used before pancreatic surgery.
•	Between 2008 and 2016, 516 patients underwent distal pancreatectomy for pancreatic cancer.
•	Among them, preoperative EUS-FNA was performed in 197 patients.</notes>
			<notesNormalized>•	in our center, eus-fna have been increasingly used before pancreatic surgery.
•	between 2008 and 2016, 516 patients underwent distal pancreatectomy for pancreatic cancer.
•	among them, preoperative eus-fna was performed in 197 patients.</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;•	In our center, EUS-FNA have been increasingly used before pancreatic surgery.&lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;•	Between 2008 and 2016, 516 patients underwent distal pancreatectomy for pancreatic cancer.&lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;•	Among them, preoperative EUS-FNA was performed in 197 patients.&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Trends in the use of EUS-FNA/B in patients with resectable distal pancreatic cancer
Between December 2007 to May 2016
The 516 patients underwent distal pancreatectomy for PCa.
Preoperative EUS-FNA/B was performed in 197 patients.</text>
		</slide>
		<slide index="14" title="Flowchart" titleNormalized="flowchart" src="slide15.swf" size="3173" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset14" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="27.1930002"/>
			</animationSteps>
			<notes>•	During the study periods, EUS-FNA/B was performed in 2,790 patients for suspected PCa. 
•	Among them, EUS-FNA/B was performed in 270 patients who were suspected of resectable pancreas body/tail cancer on CT or MRI. 
</notes>
			<notesNormalized>•	during the study periods, eus-fna/b was performed in 2,790 patients for suspected pca. 
•	among them, eus-fna/b was performed in 270 patients who were suspected of resectable pancreas body/tail cancer on ct or mri. 
</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;•	During the study periods, EUS-FNA/B was performed in 2,790 patients for suspected PCa. &lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;•	Among them, EUS-FNA/B was performed in 270 patients who were suspected of resectable pancreas body/tail cancer on CT or MRI. &lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Flowchart
EUS FNA/B for 
 R/O pancreatic cancer
(N=2,790)
EUS-FNA/B for 
R/O pancreatic body/tail cancer
(N=1,121)
EUS-FNA/B for
R/O pancreatic body/tail cancer, 
Resectable (N=270)
EUS-FNA/B for 
R/O pancreatic head/uncinate 
process cancer (N=1,669)
R/O pancreatic body/tail cancer, 
unresectable (N=851)</text>
		</slide>
		<slide index="15" title="Flowchart" titleNormalized="flowchart" src="slide16.swf" size="6396" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset15" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="14.1799998"/>
			</animationSteps>
			<notes>•	After EUS-FNA/B, 163 patients were identified as PCa.</notes>
			<notesNormalized>•	after eus-fna/b, 163 patients were identified as pca.</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;•	After EUS-FNA/B, 163 patients were identified as PCa.&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Flowchart
EUS-FNA/B for 
R/O pancreatic body/tail cancer, 
Resectable (N=270)
Biopsy-proven
pancreatic cancer
(N=163)
Surgery (N=159)
Refuse surgery (N=4)
Negative for malignancy (N=82)
Medical treatment (N=11)
CTx (N=2)
Steroid Tx (N=8)
TB med (N=1)
Observation (N=7)
Other diagnosis (N=25)
AIP (N=7)
NET (N=9)
SPN (N=5)
Lymphoma (N=2)
Eosinophilic pancreatitis (N=1)
Tuberculosis (N=1)
Surgery (N=32)
Pancreatic cancer (N=19)
NET (N=7)
Chronic pancreatitis (N=3)
SPN (N=2)
AIP (N=1)
Observation
 (N=57)
Improvement 
(N=22)
No change 
(N=17)
Aggravation 
(N=9)
F/U loss (N=9)</text>
		</slide>
		<slide index="16" title="Flowchart" titleNormalized="flowchart" src="slide17.swf" size="6409" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset16" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="15.9190001"/>
			</animationSteps>
			<notes>•	25 patients were diagnosed as AIP, NET, SPN, lymphoma, eosinophilic pancreatitis or tuberculosis.</notes>
			<notesNormalized>•	25 patients were diagnosed as aip, net, spn, lymphoma, eosinophilic pancreatitis or tuberculosis.</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;•	25 patients were diagnosed as AIP, NET, SPN, lymphoma, eosinophilic pancreatitis or tuberculosis.&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Flowchart
EUS-FNA/B for 
R/O pancreatic body/tail cancer, 
Resectable (N=270)
Biopsy-proven
pancreatic cancer
(N=163)
Surgery (N=159)
Refuse surgery (N=4)
Negative for malignancy (N=82)
Medical treatment (N=11)
CTx (N=2)
Steroid Tx (N=8)
TB med (N=1)
Observation (N=7)
Other diagnosis (N=25)
AIP (N=7)
NET (N=9)
SPN (N=5)
Lymphoma (N=2)
Eosinophilic pancreatitis (N=1)
Tuberculosis (N=1)
Surgery (N=32)
Pancreatic cancer (N=19)
NET (N=7)
Chronic pancreatitis (N=3)
SPN (N=2)
AIP (N=1)
Observation
 (N=57)
Improvement 
(N=22)
No change 
(N=17)
Aggravation 
(N=9)
F/U loss (N=9)</text>
		</slide>
		<slide index="17" title="Flowchart" titleNormalized="flowchart" src="slide18.swf" size="6505" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset17" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="21.0530009"/>
			</animationSteps>
			<notes>•	82 patients had negative results for pancreatic cancer.
•	Among them, 25 patients underwent surgery based on clinical findings favor pancreatic cancer. 
•	And watchful observation was performed in 57 patients. 
</notes>
			<notesNormalized>•	82 patients had negative results for pancreatic cancer.
•	among them, 25 patients underwent surgery based on clinical findings favor pancreatic cancer. 
•	and watchful observation was performed in 57 patients. 
</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;•	82 patients had negative results for pancreatic cancer.&lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;•	Among them, 25 patients underwent surgery based on clinical findings favor pancreatic cancer. &lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;•	And watchful observation was performed in 57 patients. &lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Flowchart
EUS-FNA/B for 
R/O pancreatic body/tail cancer, 
Resectable (N=270)
Biopsy-proven
pancreatic cancer
(N=163)
Surgery (N=159)
Refuse surgery (N=4)
Negative for malignancy (N=82)
Medical treatment (N=11)
CTx (N=2)
Steroid Tx (N=8)
TB med (N=1)
Observation (N=7)
Other diagnosis (N=25)
AIP (N=7)
NET (N=9)
SPN (N=5)
Lymphoma (N=2)
Eosinophilic pancreatitis (N=1)
Tuberculosis (N=1)
Surgery (N=32)
Pancreatic cancer (N=19)
NET (N=7)
Chronic pancreatitis (N=3)
SPN (N=2)
AIP (N=1)
Observation
 (N=57)
Improvement 
(N=22)
No change 
(N=17)
Aggravation 
(N=9)
F/U loss (N=9)
25 patients</text>
		</slide>
		<slide index="18" title="Flowchart" titleNormalized="flowchart" src="slide19.swf" size="6392" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset18" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="13.1790003"/>
			</animationSteps>
			<notes>•	In 22 patients, mass improved, and 17 patients had no change of mass for more than 1 year.

</notes>
			<notesNormalized>•	in 22 patients, mass improved, and 17 patients had no change of mass for more than 1 year.

</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;•	In 22 patients, mass improved, and 17 patients had no change of mass for more than 1 year.&lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;</notesHtml>
			<text>Flowchart
EUS-FNA/B for 
R/O pancreatic body/tail cancer, 
Resectable (N=270)
Biopsy-proven
pancreatic cancer
(N=163)
Surgery (N=159)
Refuse surgery (N=4)
Negative for malignancy (N=82)
Medical treatment (N=11)
CTx (N=2)
Steroid Tx (N=8)
TB med (N=1)
Observation (N=7)
Other diagnosis (N=25)
AIP (N=7)
NET (N=9)
SPN (N=5)
Lymphoma (N=2)
Eosinophilic pancreatitis (N=1)
Tuberculosis (N=1)
Surgery (N=32)
Pancreatic cancer (N=19)
NET (N=7)
Chronic pancreatitis (N=3)
SPN (N=2)
AIP (N=1)
Observation
 (N=57)
Improvement 
(N=22)
No change 
(N=17)
Aggravation 
(N=9)
F/U loss (N=9)</text>
		</slide>
		<slide index="19" title="Flowchart" titleNormalized="flowchart" src="slide20.swf" size="6557" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset19" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="22.9889998"/>
			</animationSteps>
			<notes>•	As a results, 21% of patients could avoid surgery due to preoperative EUS-FNA.
•	Of course, selection bias might affect the results, because preoperative EUS-FNA might have been performed in patients with atypical image findings.</notes>
			<notesNormalized>•	as a results, 21% of patients could avoid surgery due to preoperative eus-fna.
•	of course, selection bias might affect the results, because preoperative eus-fna might have been performed in patients with atypical image findings.</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;•	As a results, 21% of patients could avoid surgery due to preoperative EUS-FNA.&lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;•	Of course, selection bias might affect the results, because preoperative EUS-FNA might have been performed in patients with atypical image findings.&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Flowchart
EUS-FNA/B for 
R/O pancreatic body/tail cancer, 
Resectable (N=270)
Biopsy-proven
pancreatic cancer
(N=163)
Surgery (N=159)
Refuse surgery (N=4)
Negative for malignancy (N=82)
Medical treatment (N=11)
CTx (N=2)
Steroid Tx (N=8)
TB med (N=1)
Observation (N=7)
Other diagnosis (N=25)
AIP (N=7)
NET (N=9)
SPN (N=5)
Lymphoma (N=2)
Eosinophilic pancreatitis (N=1)
Tuberculosis (N=1)
Surgery (N=32)
Pancreatic cancer (N=19)
NET (N=7)
Chronic pancreatitis (N=3)
SPN (N=2)
AIP (N=1)
Observation
 (N=57)
Improvement 
(N=22)
No change 
(N=17)
Aggravation 
(N=9)
F/U loss (N=9)
“21% (57/270) could avoid surgery.”</text>
		</slide>
		<slide index="20" title="Cancer free survival after distal pancreatectomy" titleNormalized="cancer free survival after distal pancreatectomy" src="slide21.swf" size="20314" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset20" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="19.7520003"/>
			</animationSteps>
			<notes>•	Cancer free survival in patient undergoing preoperative EUS-FNA was similar with that in patients who did not undergo EUS-FNA.
•	There was no significant difference between two groups.</notes>
			<notesNormalized>•	cancer free survival in patient undergoing preoperative eus-fna was similar with that in patients who did not undergo eus-fna.
•	there was no significant difference between two groups.</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;•	Cancer free survival in patient undergoing preoperative EUS-FNA was similar with that in patients who did not undergo EUS-FNA.&lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;•	There was no significant difference between two groups.&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Cancer free survival after distal pancreatectomy
Cancer free survival (months)
Survival probability (%)
 EUS-FNA group
 Non-EUS-FNA group
 P=0.426</text>
		</slide>
		<slide index="21" title="Overall survival after distal pancreatectomy" titleNormalized="overall survival after distal pancreatectomy" src="slide22.swf" size="19403" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset21" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="10.2430004"/>
			</animationSteps>
			<notes>•	Overall survival after distal pancreatectomy was not significantly different between two groups.</notes>
			<notesNormalized>•	overall survival after distal pancreatectomy was not significantly different between two groups.</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;•	Overall survival after distal pancreatectomy was not significantly different between two groups.&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Overall survival after distal pancreatectomy
Overall survival in months
Survival probability (%)
 EUS-FNA group
 Non-EUS-FNA group
 P=0.551</text>
		</slide>
		<slide index="22" title="Preoperative EUS-FNA/B" titleNormalized="preoperative eus-fna/b" src="slide23.swf" size="3005" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset22" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="29.7989992"/>
			</animationSteps>
			<notes>•	During EUS-FNA, mean number of needle passage was 3.2 times.
•	The most commonly used needle is the 22-gauge needle.
•	Post-procedural pancreatitis associated with EUS-FNA occurred in 1 patient. 
•	Isolated recurred tumor at the stomach wall was observed in 2 patients.</notes>
			<notesNormalized>•	during eus-fna, mean number of needle passage was 3.2 times.
•	the most commonly used needle is the 22-gauge needle.
•	post-procedural pancreatitis associated with eus-fna occurred in 1 patient. 
•	isolated recurred tumor at the stomach wall was observed in 2 patients.</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;•	During EUS-FNA, mean number of needle passage was 3.2 times.&lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;•	The most commonly used needle is the 22-gauge needle.&lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;•	Post-procedural pancreatitis associated with EUS-FNA occurred in 1 patient. &lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;•	Isolated recurred tumor at the stomach wall was observed in 2 patients.&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Preoperative EUS-FNA/B
Needle passage (mean±SD)
3.2 ± 1.3 times
Needle type
 19G
13.5% 
 22G
64.8% 
 25G
21.8%
Adverse events
 Pancreatitis
1
 Gastric recurrence
2</text>
		</slide>
		<slide index="23" title="55 y/o male with pancreas mass" titleNormalized="55 y/o male with pancreas mass" src="slide24.swf" size="414850" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset23" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="16.9190001"/>
			</animationSteps>
			<notes>•	A 55 years old man had pancreas tail mass on CT scan. 
•	EUS-FNA was performed and revealed adenocarcinoma.
•	He underwent distal pancreatectomy and splenectomy.</notes>
			<notesNormalized>•	a 55 years old man had pancreas tail mass on ct scan. 
•	eus-fna was performed and revealed adenocarcinoma.
•	he underwent distal pancreatectomy and splenectomy.</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;•	A 55 years old man had pancreas tail mass on CT scan. &lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;•	EUS-FNA was performed and revealed adenocarcinoma.&lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;•	He underwent distal pancreatectomy and splenectomy.&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>55 y/o male with pancreas mass
“Ductal adenocarcinoma”</text>
		</slide>
		<slide index="24" title="55 y/o male – 11 months later" titleNormalized="55 y/o male – 11 months later" src="slide25.swf" size="341650" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset24" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="36.2690005"/>
			</animationSteps>
			<notes>•	11 months after surgery, follow-up CT scan showed low density mass at the stomach wall. 
•	Endoscopy showed ulcerofungating mass at the posterior wall of stomach body.
•	Biopsy revealed recurred pancreatic cancer.
•	Unfortunately, in this patient, tumor recurred at the needle puncture site during EUS-FNA. </notes>
			<notesNormalized>•	11 months after surgery, follow-up ct scan showed low density mass at the stomach wall. 
•	endoscopy showed ulcerofungating mass at the posterior wall of stomach body.
•	biopsy revealed recurred pancreatic cancer.
•	unfortunately, in this patient, tumor recurred at the needle puncture site during eus-fna.</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;•	11 months after surgery, follow-up CT scan showed low density mass at the stomach wall. &lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;•	Endoscopy showed ulcerofungating mass at the posterior wall of stomach body.&lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;•	Biopsy revealed recurred pancreatic cancer.&lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;•	Unfortunately, in this patient, tumor recurred at the needle puncture site during EUS-FNA. &lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>55 y/o male – 11 months later</text>
		</slide>
		<slide index="25" title="Outcomes of preoperative EUS-FNA/B (for PCa)" titleNormalized="outcomes of preoperative eus-fna/b (for pca)" src="slide26.swf" size="3171" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset25" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="43.0790018"/>
			</animationSteps>
			<notes>•	In patients underwent distal pancreatectomy for pancreatic cancer, diagnostic accuracy of EUS-FNA or FNB for pancreatic cancer is 90.4%. 
•	Sensitivity was 87.2%, specificity was 100%, positive predictive value was 100%, but negative predictive value was 73%. 
•	Relatively low negative predictive value may be the problem. 
•	Onsite cytopathologists are not available in our center. 

</notes>
			<notesNormalized>•	in patients underwent distal pancreatectomy for pancreatic cancer, diagnostic accuracy of eus-fna or fnb for pancreatic cancer is 90.4%. 
•	sensitivity was 87.2%, specificity was 100%, positive predictive value was 100%, but negative predictive value was 73%. 
•	relatively low negative predictive value may be the problem. 
•	onsite cytopathologists are not available in our center. 

</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;•	In patients underwent distal pancreatectomy for pancreatic cancer, diagnostic accuracy of EUS-FNA or FNB for pancreatic cancer is 90.4%. &lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;•	Sensitivity was 87.2%, specificity was 100%, positive predictive value was 100%, but negative predictive value was 73%. &lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;•	Relatively low negative predictive value may be the problem. &lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;•	Onsite cytopathologists are not available in our center. &lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;</notesHtml>
			<text>Outcomes of preoperative EUS-FNA/B (for PCa)
%
EUS-FNA/B
N = 197
 Diagnostic accuracy
90.4%
 Sensitivity
87.2%
 Specificity
100%
 Positive predictive value (PPV) 
100%
 Negative predictive value (NPV)
72.9%
No onsite cytopathologists</text>
		</slide>
		<slide index="26" title="Negative preoperative EUS-FNA results" titleNormalized="negative preoperative eus-fna results" src="slide27.swf" size="2944" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset26" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="51.5839991"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
			<text>Negative preoperative EUS-FNA results
Two retrospective studies found that, for indeterminate cytopathological diagnoses, several clinical conditions (e. g., weight loss and bile duct obstruction) were associated with a final diagnosis of malignancy. 

Surgery is recommended in patients with “suspicious” cytopathology and those clinical predictors for PCa, if the mass is resectable.

Repeat tissue sampling is recommended in patients with unresectable mass.
Alston et al. Cancer Cytopathol 2016;124:53–57
Alston et al. Cancer Cytopathol 2014;122:428–434</text>
		</slide>
		<slide index="27" title="64 y/o male" titleNormalized="64 y/o male" src="slide28.swf" size="320902" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset27" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="38.3390002"/>
			</animationSteps>
			<notes>•	Let me show you a case. A 64-year-old man had low density mass at the pancreas body. He had uncontrolled diabetes and history of idiopathic acute pancreatitis. CA 19-9 level was elevated.
•	EUS-FNA was done. But it did not show malignancy. 
•	However, because he had several clinical conditions suspicious for pancreatic cancer, distal pancreatectomy was done. </notes>
			<notesNormalized>•	let me show you a case. a 64-year-old man had low density mass at the pancreas body. he had uncontrolled diabetes and history of idiopathic acute pancreatitis. ca 19-9 level was elevated.
•	eus-fna was done. but it did not show malignancy. 
•	however, because he had several clinical conditions suspicious for pancreatic cancer, distal pancreatectomy was done.</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;•	Let me show you a case. A 64-year-old man had low density mass at the pancreas body. He had uncontrolled diabetes and history of idiopathic acute pancreatitis. CA 19-9 level was elevated.&lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;•	EUS-FNA was done. But it did not show malignancy. &lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;•	However, because he had several clinical conditions suspicious for pancreatic cancer, distal pancreatectomy was done. &lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>64 y/o male
Uncontrolled DM
Idiopathic acute pancreatitis
CA 19-9 118 U/mL
“Negative for malignancy”
“Ductal adenocarcinoma”</text>
		</slide>
		<slide index="28" title="54 y/o male with pancreatic mass" titleNormalized="54 y/o male with pancreatic mass" src="slide29.swf" size="361604" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset28" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="36.4019999"/>
			</animationSteps>
			<notes>•	A 60-year-old man was transferred for work up of low-density mass on CT scan found during routine heath checkup. 
•	He had no specific symptom and risk factors for pancreatic cancer. And tumor marker was within normal range.
•	EUS-FNB revealed focal inflammation. So close follow-up instead of surgery was done. After one moth follow-up CT scan showed improved mass lesion.</notes>
			<notesNormalized>•	a 60-year-old man was transferred for work up of low-density mass on ct scan found during routine heath checkup. 
•	he had no specific symptom and risk factors for pancreatic cancer. and tumor marker was within normal range.
•	eus-fnb revealed focal inflammation. so close follow-up instead of surgery was done. after one moth follow-up ct scan showed improved mass lesion.</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;•	A 60-year-old man was transferred for work up of low-density mass on CT scan found during routine heath checkup. &lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;•	He had no specific symptom and risk factors for pancreatic cancer. And tumor marker was within normal range.&lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;•	EUS-FNB revealed focal inflammation. So close follow-up instead of surgery was done. After one moth follow-up CT scan showed improved mass lesion.&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>54 y/o male with pancreatic mass
“Focal pancreatitis”</text>
		</slide>
		<slide index="29" title="54 y/o male with pancreatic mass" titleNormalized="54 y/o male with pancreatic mass" src="slide30.swf" size="381286" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset29" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="35.0339998"/>
			</animationSteps>
			<notes>•	A 54-year-old man had a low-density mass at the pancreas tail portion on CT scan. PET scan revealed hot uptake at the same site.
•	He recently diagnosed with new onset diabetes. 
•	EUS-FNB was done, and biopsy revealed autoimmune pancreatitis.
•	After steroid treatment, mass improved. 
•	Due to EUS-guided biopsy, surgery could be avoided. </notes>
			<notesNormalized>•	a 54-year-old man had a low-density mass at the pancreas tail portion on ct scan. pet scan revealed hot uptake at the same site.
•	he recently diagnosed with new onset diabetes. 
•	eus-fnb was done, and biopsy revealed autoimmune pancreatitis.
•	after steroid treatment, mass improved. 
•	due to eus-guided biopsy, surgery could be avoided.</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;•	A 54-year-old man had a low-density mass at the pancreas tail portion on CT scan. PET scan revealed hot uptake at the same site.&lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;•	He recently diagnosed with new onset diabetes. &lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;•	EUS-FNB was done, and biopsy revealed autoimmune pancreatitis.&lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;•	After steroid treatment, mass improved. &lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;•	Due to EUS-guided biopsy, surgery could be avoided. &lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>54 y/o male with pancreatic mass
“Autoimmune pancreatitis”</text>
		</slide>
		<slide index="30" title="Conclusions" titleNormalized="conclusions" src="slide31.swf" size="639483" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset30" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="31.3299994"/>
			</animationSteps>
			<notes>•	Preoperative EUS-FNA/B is not associated with increased risk of cancer-speciﬁc or overall survival in the patients with resected pancreatic cancer.
•	Some patients can avoid unnecessary surgery due to preoperative EUS-FNA/B.
•	We also have to keep in mind its potential risks such as needle tract seeding.

</notes>
			<notesNormalized>•	preoperative eus-fna/b is not associated with increased risk of cancer-speciﬁc or overall survival in the patients with resected pancreatic cancer.
•	some patients can avoid unnecessary surgery due to preoperative eus-fna/b.
•	we also have to keep in mind its potential risks such as needle tract seeding.

</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;•	Preoperative EUS-FNA/B is not associated with increased risk of cancer-speciﬁc or overall survival in the patients with resected pancreatic cancer.&lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;•	Some patients can avoid unnecessary surgery due to preoperative EUS-FNA/B.&lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;•	We also have to keep in mind its potential risks such as needle tract seeding.&lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;</notesHtml>
			<text>Preoperative EUS-FNA/B is not associated with increased risk of cancer-speciﬁc or overall survival in the patients with resected pancreatic cancer.
Some patients can avoid unnecessary surgery due to preoperative EUS-FNA/B.
We also have to keep in mind its potential risks.

Conclusions</text>
		</slide>
		<slide index="31" title="Thank you. 감사합니다." titleNormalized="thank you. 감사합니다." src="slide32.swf" size="817789" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset31" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="2.5010001"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
			<text>Thank you. 감사합니다.</text>
		</slide>
	</slides>
</presentation>
